Daxor Corporation (DXR)vsMerck & Company Inc (MRK)
DXR
Daxor Corporation
$10.80
+1.41%
HEALTHCARE · Cap: $59.73M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 243578015% more annual revenue ($65.01B vs $26,690). DXR leads profitability with a 34359.0% profit margin vs 28.1%. DXR trades at a lower P/E of 6.3x. MRK earns a higher WallStSmart Score of 59/100 (C).
DXR
Hold45
out of 100
Grade: D+
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXR.
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 34359 of every $100 in revenue as profit
Earnings expanding 329.3% YoY
Every $100 of equity generates 23 in profit
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 82.6%
Negative free cash flow — burning cash
Operating margin of -9661.0%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 34359.0% and operating margin at -9661.0%.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : DXR
The primary concerns for DXR are Market Cap, Revenue Growth, Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
DXR profiles as a declining stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 45/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?